271. Full-Length Antibody Therapy Mediated by Adenovirus in Rodent and Non-Primate Animal Models

Therapeutic monoclonal antibody is increasingly applied in clinic with great clinical success, while its widespread application is limited by antibody manufacturing capability. Adenovirus is considered ad the one of the most proper vector for pre-clinical and clinical application, however, the application of adenoviral vector is restricted by CAR expression on the target cells. Thus adenovirus mediating anti-tumor antigen antibody expression in non-tumor cells or tumor cells is a novel strategy for cancer gene therapy. Herein we present an adenoviral delivery system that allows in vivo sufficient and sustained full-length antibody expression.